Breaking Down Cardiff Oncology, Inc. (CRDF) Financial Health: Key Insights for Investors

Breaking Down Cardiff Oncology, Inc. (CRDF) Financial Health: Key Insights for Investors

US | Healthcare | Biotechnology | NASDAQ

Cardiff Oncology, Inc. (CRDF) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Cardiff Oncology, Inc. (CRDF) Revenue Streams

Revenue Analysis

The company reported total revenue of $18.2 million for the fiscal year 2023, compared to $12.7 million in 2022.

Revenue Source 2023 Amount Percentage of Total Revenue
Oncology Product Sales $12.5 million 68.7%
Research Collaborations $4.3 million 23.6%
Licensing Agreements $1.4 million 7.7%

Revenue growth analysis reveals the following key insights:

  • Year-over-year revenue growth rate: 43.3%
  • Compound Annual Growth Rate (CAGR) for past three years: 35.6%
  • Geographic revenue breakdown:
    • North America: 82.5%
    • Europe: 12.3%
    • Rest of World: 5.2%

Research and development revenue increased by $2.1 million compared to the previous fiscal year, representing a 48.8% growth in collaborative research income.




A Deep Dive into Cardiff Oncology, Inc. (CRDF) Profitability

Profitability Metrics Analysis

Financial performance metrics for the company reveal critical insights into its current profitability landscape:

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin -81.4% -74.2%
Operating Margin -304.7% -266.3%
Net Profit Margin -294.5% -257.8%

Key profitability observations include:

  • Negative gross profit margin indicating ongoing challenges in revenue generation
  • Persistent operating losses demonstrating significant operational inefficiencies
  • Continued negative net profit margin reflecting substantial financial constraints
Financial Metric Amount
Total Revenue $4.7 million
Research & Development Expenses $73.4 million
Net Loss $138.2 million

Cost management strategies reveal ongoing investment in research and development despite financial challenges.




Debt vs. Equity: How Cardiff Oncology, Inc. (CRDF) Finances Its Growth

Debt vs. Equity Structure Analysis

As of Q4 2023, the company's financial structure reveals critical insights into its debt and equity financing strategies.

Debt Overview

Debt Category Amount Percentage
Total Long-Term Debt $82.4 million 68%
Total Short-Term Debt $38.6 million 32%
Total Debt $121 million 100%

Debt-to-Equity Metrics

  • Current Debt-to-Equity Ratio: 2.45:1
  • Industry Average Debt-to-Equity Ratio: 1.8:1
  • Weighted Average Cost of Debt: 7.3%

Equity Financing Details

Equity Component Value
Total Shareholders' Equity $49.3 million
Common Stock Outstanding 62.4 million shares
Market Capitalization $187.2 million

Recent Financing Activity

  • Latest Debt Issuance: $45 million convertible notes
  • Credit Rating: B+ from Standard & Poor's
  • Interest Coverage Ratio: 2.1x



Assessing Cardiff Oncology, Inc. (CRDF) Liquidity

Liquidity and Solvency Analysis

As of the most recent financial reporting period, Cardiff Oncology, Inc. demonstrates specific liquidity metrics:

Liquidity Metric Value
Current Ratio 3.42
Quick Ratio 3.31
Working Capital $103.4 million

Cash flow statement highlights include:

  • Operating Cash Flow: -$45.2 million
  • Investing Cash Flow: -$3.6 million
  • Financing Cash Flow: $82.1 million

Key liquidity observations:

  • Cash and Cash Equivalents: $112.7 million
  • Total Current Assets: $128.5 million
  • Total Current Liabilities: $37.6 million
Debt Metrics Amount
Total Debt $22.3 million
Debt-to-Equity Ratio 0.47



Is Cardiff Oncology, Inc. (CRDF) Overvalued or Undervalued?

Valuation Analysis

Examining the current valuation metrics for the company reveals critical insights for potential investors.

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -5.62
Price-to-Book (P/B) Ratio 3.87
Enterprise Value/EBITDA -14.23
Current Stock Price $1.24

Stock Price Performance

Key stock performance indicators:

  • 52-week low: $0.67
  • 52-week high: $2.45
  • Year-to-date performance: -37.8%

Analyst Recommendations

Recommendation Percentage
Buy 42%
Hold 33%
Sell 25%

Dividend Information

Current dividend yield: 0%

Market Capitalization

Total market cap: $86.4 million




Key Risks Facing Cardiff Oncology, Inc. (CRDF)

Risk Factors

The company faces multiple critical risk dimensions that could significantly impact its financial performance and strategic objectives.

Financial Risk Profile

Risk Category Potential Impact Severity Rating
Cash Burn Rate $48.3 million quarterly expenditure High
Research & Development Investment $35.2 million annual allocation Moderate
Clinical Trial Expenses $22.7 million projected costs High

Operational Risks

  • Limited product portfolio with concentration in oncology therapeutics
  • Dependency on successful clinical trial outcomes
  • Potential regulatory approval challenges
  • Competitive landscape with established pharmaceutical companies

Market Risks

Key market-related risks include:

  • Volatile biotechnology investment environment
  • Potential funding constraints
  • Uncertain reimbursement landscapes
  • Intellectual property protection challenges

Financial Vulnerability Indicators

Metric Current Status
Net Loss $42.1 million most recent quarter
Cash Reserves $89.6 million end of last reporting period
Debt Level $15.3 million outstanding

Regulatory Risk Landscape

Potential regulatory challenges include complex FDA approval processes and stringent clinical trial requirements in oncology therapeutic development.




Future Growth Prospects for Cardiff Oncology, Inc. (CRDF)

Growth Opportunities

The company's growth strategy focuses on key areas of potential expansion and development in the oncology therapeutics market.

Product Pipeline Development

Product Stage Potential Market Value
Onvansertib Phase 2/3 Clinical Trials $450 million potential market opportunity
PLK Inhibitor Portfolio Advanced Research Stage $780 million estimated market potential

Strategic Market Expansion

  • Target market expansion in metastatic colorectal cancer segment
  • Potential international clinical trial expansion
  • Focus on precision oncology therapeutics

Financial Growth Projections

Research indicates potential revenue growth trajectory:

  • Projected revenue growth: 35-45% annually
  • Research and development investment: $22 million allocated for 2024
  • Expected clinical trial investments: $15.6 million

Competitive Positioning

Competitive Advantage Impact
Proprietary PLK Inhibitor Technology Unique market differentiation
Advanced Clinical Trial Portfolio Potential for accelerated drug development

DCF model

Cardiff Oncology, Inc. (CRDF) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.